Morrison & Foerster advised MyChem, a privately held provider of proprietary, ultra-pure nucleotides to customers in the diagnostics, pharma, genomics and research markets, in connection with its sale to Maravai (NASDAQ: MRVI). Consideration for the sale included $240 million in cash at closing with the potential for additional contingent cash consideration based on achievement of certain conditions after closing.
MyChem’s products include modified nucleotides and other inputs used for mRNA synthesis. MyChem’s ultra-pure nucleotides are used in a variety of applications to advance the development of biotechnology research, diagnostic and therapeutic applications.
The MoFo deal team was led by San Diego corporate partner Jim Krenn, together with San Diego corporate associates Andrew Dixon, Pat Boyle and Brooke Maker. The wider team included Boston TTG partner Matt Karlyn, Boston TTG associate Mai Zymaris, New York tax partner Dave Sturgeon, San Diego tax partner Shane Shelley, San Francisco tax associate Adam Nguyen, San Diego tax associate Kristie Espiritu, Boston tax associate Kevin Brown, San Francisco executive compensation partner Amanda Hines Gold, San Francisco executive compensation associate Yuan Xia, Palo Alto labor of counsel Ossie Cousins, San Diego environmental associate Krista DeBoer, Washington D.C. antitrust partner Vishal Mehta, Washington D.C. antitrust associate Eric Olson, San Francisco FTG of counsel Vince Novak, Washington D.C. FDA/regulatory of counsel Brigid Bondoc, New York FDA/regulatory partner Bethany Hills, Washington D.C. CFIUS of counsel Aki Bayz and many others.